Microbix Biosystems Inc
Open
–
Prev. Close
–
High
–
Low
–
Market Snapshot
$34.64M
21.5
-0.03
$16.76M
70
Microbix Biosystems, Inc. engages in developing and commercializing proprietary biological and technology solutions for human health and wellbeing. The company is headquartered in Mississauga, Ontario. The firm develops and commercializes proprietary biological and technology solutions for human health and wellbeing. The company manufactures a range of critical biological materials and medical devices for the global diagnostics industry, notably test ingredients (Antigen business) used in immunoassays, quality assessment and proficiency testing controls (QAPsTM business), and sample collection devices (DxTMTM business). The firm operates in two ways: (i) the development, manufacturing, and sale of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples, and (ii) the development and commercialization of novel and proprietary products or technologies such as Kinlytic. It's Kinlytic Urokinase, a biologic thrombolytic drug used to treat blood clots.
Microbix Biosystems, Inc. engages in developing and commercializing proprietary biological and technology solutions for human health and wellbeing. The company is headquartered in Mississauga, Ontario. The firm develops and commercializes proprietary biological and technology solutions for human health and wellbeing. The company manufactures a range of critical biological materials and medical devices for the global diagnostics industry, notably test ingredients (Antigen business) used in immunoassays, quality assessment and proficiency testing controls (QAPsTM business), and sample collection devices (DxTMTM business). The firm operates in two ways: (i) the development, manufacturing, and sale of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples, and (ii) the development and commercialization of novel and proprietary products or technologies such as Kinlytic. It's Kinlytic Urokinase, a biologic thrombolytic drug used to treat blood clots.
Recently from Cashu
Couldn't load Cashu news
Something went wrong. Try refreshing the page.